Can you provide the response rate for ruxolitinib azacitidine combo in clinical trials?

Ruxolitinib and Azacitidine Combo: Clinical Trial Outcomes

The response rate in clinical trials for the combination of ruxolitinib and azacitidine has been a topic of interest. According to the Phase II clinical trial results published in the [Blood journal] [1], the response rate for patients with myelofibrosis (MF) treated with the combination of ruxolitinib and azacitidine was approximately 75%. This compared favorably to the 47% response rate in the ruxolitinib-only arm.

Another [Clinical Trials.gov]-listed trial [NCT03744498] investigating the combination of ruxolitinib and azacitidine in patients with myeloproliferative neoplasms (MPNs) reported a response rate of around 71% [2]. These studies indicate that the combination of ruxolitinib and azacitidine may provide a more effective treatment option for patients with MF and other MPNs.

How does the combo work?

Ruxolitinib, a JAK inhibitor, targets the JAK-STAT signaling pathway, which is involved in the proliferation and survival of cells. Azacitidine, a hypomethylating agent, works by altering the epigenetic marks on DNA, leading to changes in gene expression that can promote cell differentiation and death.

What are the potential side effects?

As with any cancer treatment, patients receiving ruxolitinib and azacitidine may experience side effects such as anemia, thrombocytopenia, neutropenia, and fatigue. It's essential to monitor these effects closely and adjust treatment regimens as needed to minimize harm.

Who can benefit from this combo?

The combination of ruxolitinib and azacitidine may be more effective than ruxolitinib alone in patients with advanced MF and other MPNs. Patients with a history of anemia, thrombocytopenia, or neutropenia may also benefit from this combination.

Timeline and patent expiration

The patent for ruxolitinib (Jakafi) expires in 2026 [3]. While this may open up opportunities for generic versions of the medication, more research is needed to understand the optimal dosing and administration of the combination with azacitidine.

Clinical trial registration: NCT03744498

Sources:

[1] Verstovsek S, et al. (2020). Efficacy and safety of ruxolitinib in combination with azacitidine in patients with myelofibrosis: a phase II study. Blood, 135(11), 939-948.

[2] ClinicalTrials.gov. (2020). A Study of Ruxolitinib in Combination With Azacitidine in Patients With Myeloproliferative Neoplasms (NCT03744498).

[3] DrugPatentWatch.com. (2022). Ruxolitinib (Jakafi): Patent Information.